Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RO7502175 |
| Synonyms | |
| Therapy Description |
RO7502175 is an afucosylated antibody targeting CCR8, which induces depletion of CCR8+ T-regulatory cells from the tumor microenvironment, potentially resulting in enhanced antitumor activity (PMID: 38486310). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RO7502175 | RO-7502175|RO 7502175 | CCR8 Antibody 13 | RO7502175 is an afucosylated antibody targeting CCR8, which induces depletion of CCR8+ T-regulatory cells from the tumor microenvironment, potentially resulting in enhanced antitumor activity (PMID: 38486310). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05581004 | Phase I | Atezolizumab + RO7502175 RO7502175 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | SWE | NLD | GRC | ESP | CAN | BEL | AUS | 2 |